Search for a trial

Imaging and angiogenesis of malignant lymphoma with dynamic MRI, H-MRS, P-MRS and FDG-PET/CT for staging, mid treatment assessment and outcome.

Evaluation of the vascularisation of malignant lymphoma and its change during therapy with DCE-MRI. Furthermore evaluation of metabolite concentration ratios and absolute measurements made with MRS techniques as a measurement of vascularisation and…

Plerixafor and G-CSF for the Mobilisation of Peripheral Blood Stem Cells for Autologous Stem Cell Transplantation in Patients with Non-Hodgkin*s Lymphoma (NHL), Hodgkin*s Disease (HD) or Multiple Myeloma (MM) * Safety Study in a General Autologous Transplant Population

Primary Objective: * To confirm the safety profile of plerixafor to mobilise stem cells when used in patients with lymphoma or MM who are eligible to undergo treatment with an autologous haematopoietic stem cell transplantSecondary Objectives:* To…

A Phase 1/2 study of the combination of pixantrone, etoposide, bendamustine and, in CD-20 positive tumors, rituximab in patients with relapsed aggressive non-Hodgkin lymphomas of B- or T-cell phenotype - The P[R]EBEN study

Primary Objectives- Determine the MTD of pixantrone, rituximab (only in CD20 positive tumors), etoposide, and bendamustine in *fit' patients with rel aNHL of B- or T-cell phenotype.- Evaluate the ORR and PFS using the combination of pixantrone…

*Follow that CAR!* - A prospective observational cohort study on CAR T-cell therapy for B-cell malignancies in the Netherlands

• To set up a national prospective observational cohort study of patients who have a hematological B-cell malignancy and are referred to the national CAR T-cell tumorboard for evaluation of eligibility for treatment with CAR T-cell therapy and to…

A PHASE 2, SINGLE-ARM, MULTI-COHORT, MULTI-CENTER TRIAL TO DETERMINE THE EFFICACY AND SAFETY OF JCAR017 IN ADULT SUBJECTS WITH AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMA

Primary ObjectivesCohorts 1, 2, 3, 4, and 5• Determine the efficacy, defined as overall response rate (ORR), of JCAR017 in subjects with aggressive B-cell non-Hodgkin lymphomaCohort 7• Evaluate the safety of JCAR017 treatment in subjects intended to…

*Health-Related Quality of Life and disease-specific symptoms among Lymphoma and Multiple Myeloma survivors: A longitudinal PROFILES registry study. VITA-study*

The main objective is to assess HRQoL and (disease-specific) symptoms in patients with lymphoma or multiple myeloma. In addition, to identify demographic, clinical, biological, physiological and environmental characteristics of lymphoma and multiple…

LONG-TERM FOLLOW-UP PROTOCOL FOR SUBJECTS TREATED WITH GENE-MODIFIED T CELLS

This study has been transitioned to CTIS with ID 2023-504201-36-00 check the CTIS register for the current data. Per Health Authority guidelines for gene therapy medicinal products that utilize integrating vectors (eg, lentiviral vectors), long-term…

A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE C19 in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL) (ZUMA-1)

The primary objective of Phase 1 study is to evaluate the safety of axicabtagene ciloleucel regimens.The primary objective of Phase 2 pivotal study is to evaluate the efficacy of axicabtagene ciloleucel, as measured by objective response rate (ORR)…

A first-in-human dose escalation and expansion study with the SIRPα-directed monoclonal antibody BYON4228 alone and in combination with rituximab to evaluate the safety, pharmacokinetics, pharmacodynamics and efficacy in patients with relapsed/refractory CD20 positive B-cell Non-Hodgkin*s Lymphoma (NHL)

This study has been transitioned to CTIS with ID 2024-512390-27-00 check the CTIS register for the current data. The primary objectives of this trial are:• Part 1 (dose escalation): To evaluate the safety of BYON4228 alone and in combinationwith…

International cooperative prospective study for children and adolescents with standard risk ALK-positive anaplastic large cell lymphoma (ALCL) estimating the efficacy of Vinblastine.

This study has been transitioned to CTIS with ID 2022-501454-11-00 check the CTIS register for the current data. PRIMARY OBJECTIVE:- To show that it is possible to cure at least 75% of patients belonging to the SR group with Vinblastine-monotherapy…

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-X19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)

This study has been transitioned to CTIS with ID 2023-506641-35-00 check the CTIS register for the current data. The primary objective is to evaluate the efficacy of KTE-X19, as measured by objective response rate (ORR), in subjects with r/r MCL.…

A prospective, international, multi-centre, open-label,single-arm phase II study investigating the predictive value of [68Ga]Ga-PentixaFor PET imaging in primary and isolated secondary CNS lymphoma patients

Primary objective:1. To evaluate the negative predictive value (NPV) of [68Ga]Ga-PentixaFor (PTF) PET at interim examination (after 6 ± 2 weeks of induction chemotherapy) for progression-free survival (PFS). Secondary objectives:2. To evaluate the…